Biotech News

Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update

FEMASYS (FEMY)FEMASYSEarnings

$30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financing $30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financing

Related news

FEMASYS

Women's Health Medical Device Company Femasys develops office-based products for reproductive health. Its portfolio addresses permanent contraception, infertility treatment, and diagnostic evaluation of the uterus and fallopian tubes. FemBloc Permanent Contraception FemBloc is a non-surgical permanent birth-control system delivered...

Recent company news

Stock data

Close
1.26 USD
Market cap
22.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States